Mayo Clinic reports tamoxifen benefit for breast-cancer patients tied to inherited gene

December 16, 2005

One of the most commonly administered drugs for breast cancer, tamoxifen, may not be as effective for women who inherit a common genetic change, according to researchers at Mayo Clinic and the University of Michigan. The genetic change affects the levels of a crucial liver enzyme, Cytochrome P4502D6, responsible for tamoxifen metabolism.

Up to 10 percent of Caucasian patients have an inherited genetic change that affects tamoxifen metabolism -- and appear to be at higher risk of relapse while receiving tamoxifen.

The study, co-led by Mayo Clinic oncologist Matthew Goetz, M.D., and James Rae, Ph.D., of the University of Michigan, tested the most common genetic change responsible for lowering the CYP2D6 enzyme, and found that women with the genetic change were almost twice as likely to experience breast cancer relapse. Their findings are published in the Dec. 20 issue of The Journal of Clinical Oncology.

"Cytochrome P4502D6 has recently been shown to be a crucial enzymatic step responsible for activating tamoxifen to a metabolite that is nearly one hundred times more potent than tamoxifen," says Dr. Goetz. "Our study demonstrates that women who inherit a genetic change in the CYP2D6 gene that lowers the level of this enzyme appear to be at higher risk of relapse when treated with five years of tamoxifen.

"In addition to being at higher risk of relapse, the women with the genetic change also did not develop one of the most common side effects of tamoxifen -- hot flashes," says Dr. Goetz. "These findings are important, as doctors commonly co-prescribe drugs such as antidepressants for the treatment of hot flashes, and many of these drugs potently inhibit the metabolism of tamoxifen."

More than 210,000 women in the United States develop breast cancer each year. Approximately 70 percent of these are estrogen receptor (ER)-positive cases, many of which are treated with tamoxifen. The findings from this trial were derived from a large North Central Cancer Treatment Group (NCCTG) study led by James Ingle, M.D., in which women were treated with tamoxifen for five years.

Other physicians and researchers involved in the study from Mayo Clinic Cancer Center in Rochester and Jacksonville included Vera Suman, Ph.D.; Stephanie Safgren; Matthew Ames, Ph.D.; Daniel Visscher, M.D.; Carol Reynolds, M.D.; Fergus Couch, Ph.D.; Wilma Lingle, Ph.D.; Edith Perez, M.D.; and Dr. Ingle. David Flockhart, M.D., Ph.D., and Zeruesenay Desta, Ph.D., researchers from Indiana University and the Pharmacogenetics Research Network, also collaborated on this study.
-end-
The tamoxifen study was funded by the National Institutes of Health, the Commonwealth Cancer Research Foundation and the Breast Cancer Research Foundation.

For more information on breast cancer and other women's cancer research at Mayo Clinic, please see: http://mayoresearch.mayo.edu/mayo/research/womens_cancer.

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

Mayo Clinic

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.